References
- Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 46(1): 5–27
- Cohen SM, Johansson SL. Epidemiology and etiology of bladder cancer. Urol Clin North Am 1992; 19(3): 421–8
- Badalament RA, Kimmel M, Gay H, et al. The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma. Cancer 1987; 59(12): 2078–85
- Wheeless IL, Badalament RA, de Vere White RW; et al. Consensus review of the clinical utility of DNA cytometry in bladder cancer: report of the DNA Cytometry Consensus Conference. Cytometry 1993; 14(5): 478–81
- Sarosdy MF, de Vere White RW; Soloway MS, et al. Results of a multicenter trial using the BTA® test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154(2 Pt 1): 379–83
- Badalament RA, Sethi PS, Bennett WF, et al. Imaging of transitional cell carcinomas of urinary tract. In: Vogelzang NJ, Scardino PT, Shipley WU, et al, eds. Comprehensive textbook of genitourinary oncology. Baltimore: Williams & Wilkins, 1996: 371–87
- Petersen RO. Urologic pathology. 2d ed. Philadelphia: Lippincott, 1992: 326
- Badalament RA, Ortolano V, Burgers JK. Recurrent or aggressive bladder cancer: indications for adjuvant intravesical therapy. Urol Clin North Am 1992; 19(3): 485–98
- Lamm DL Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19(3): 573–80
- Wientjes MG, Badalament RA, Au JL Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacal 1993; 32(4): 255–62
- Perry JJ, Muss HB. Management of disseminated disease in the patient with bladder cancer. Urol Clin North Am 1994; 21(4): 661–72
- Wesson MF. Radiation therapy in regionally advanced bladder cancer. Urol Clin North Am 1992; 19(4): 725–34
- Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993; 329(19): 1377–82
- Herr HW; Scher HI. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 1994; 12(5): 975–80
- McDougal WS. Use of intestinal segments in the urinary tract: basic principles. In: Walsh PC. Retik AB, Stamey TA, et al, eds. Campbell's urology. 6th ed. Philadelphia: Saunders, 1992: 2595–629
- Scher HI. Systemic chemotherapy in regionally advanced bladder cancer: theoretical considerations and results. Urol Clin North Am 1992; 19(4): 747–59
- Badalament RA. Transitional cell carcinoma: a common sense approach. (Editorial) J Urol 1995; 153(1): 61–2
- Marshall VF, McCarron JR Jr. The curability of vesical cancer: greater now or then? Cancer Res 1977; 37: 2753
- Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urotheliurn: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12(II): 2264–70
- Einhorn LH, Roth BJ, Ansari R, et al. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994; 12(11): 2271–6
- Van Dekken H, Schervish EW; Pizzolo JG, et al. Simultaneous detection of fluorescent in situ hybridization and in vivo incorporated Brd U in a human bladder tumour. J Pathol 1991; 164(1): 17–22
- Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331 (19): 1259–64